Peter Anton

Dr. Peter Anton is a Professor of Medicine at the David Geffen School of Medicine at UCLA and a Research Scientist at the AIDS Healthcare Foundation. He was founding director of the UCLA Center for HIV Prevention Research and director of the UCLA Center for AIDS Research Mucosal Immunology Core Laboratory, which operated from 1987-2018. He also served as past co-director of the Center for Inflammatory Bowel Disease at UCLA.

Dr. Anton graduated magna cum laude from Harvard University and received his MD from Case Western Reserve University. He did fellowship work at the Cholera Hospital, ICDDR, in Bangladesh and a year fellowship in pathology at Cleveland’s Institute of Pathology. He performed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston Massachusetts. Dr. Anton began in his work at UCLA in 1986 with a gastroenterology fellowship and has been on faculty since 1989.

Dr. Anton’s research focuses on the degree of mucosal inflammation and altered co-receptor expression associated with HIV infection and associated therapeutic interventions, the potential use of the mucosa as a route of HIV immunization with various HIV vaccine candidates as well as microbicides for HIV mucosal prevention, investigating the interaction of HSV and HIV in mucosal pathogenesis and efforts to clarify the role of compartments in HIV pathogenesis.

Dr. Anton has been the PI on over 30 clinical trials including two Phase I HIV vaccine trials and two Phase I anti-HIV topical microbicide trials. He recently completed research as PI of the NIH IPCP U19 award “Microbicide Development Program” (MDP), with national/international sub-study sites, focusing on a developmental pipeline for rectal microbicides. These rectal microbicide efforts have continued with both the Clinical Trials Project within the second IPCP U19 Combination HIV Antiretroviral Rectal Microbicide (CHARM) which has six exploratory pre-Phase I microbicide trials and JHU’s DREAM project. His research has expanded into delayed-release vaginal drug delivery and IM/injectable drug delivery with Oak Crest Institute of Sciences’ U19 and Northwestern University’s UM1 SLAP-HIV.